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Abstract
Background: Although psycho-oncological interventions have been shown to significantly reduce symptoms of
anxiety and depression and enhance quality of life, a substantial number of patients with advanced cancer do not
receive psycho-oncological interventions tailored to their individual situation. Given the lack of reliable data on the
efficacy of psycho-oncological interventions in palliative care settings, we aim to examine the efficacy of a brief,
manualized individual psychotherapy for patients with advanced cancer: Managing Cancer and Living Meaningfully
(CALM). CALM aims to reduce depression and death anxiety, to strengthen communication with health care
providers, and to enhance hope and meaning in life. We adapted the intervention for German cancer care settings.
Methods/Design: We use a single-blinded randomized-controlled trial design with two treatment conditions:
intervention group (IG, CALM) and control group (CG). Patients in the CG receive a usual non-manualized
supportive psycho-oncological intervention (SPI). Patients are randomized between the IG and CG and assessed at
baseline (t0), after three (t1) and after 6 months (t2). We include patients with a malignant solid tumor who have
tumor stages of III or IV (UICC classification). Patients who are included in the study are at least 18 years old, speak
German fluently, score greater than or equal to nine on the PHQ-9 or/and greater than or equal to five on the
Distress Thermometer. It is further necessary that there is no evidence of severe cognitive impairments. We measure
depression, anxiety, distress, quality of life, demoralization, symptom distress, fatigue as well as spiritual well-being,
posttraumatic growth and close relationship experiences using validated questionnaires. We hypothesize that
patients in the IG will show a significantly lower level of depression 6 months after baseline compared to patients
in the CG. We further hypothesize a significant reduction in anxiety and fatigue as well as significant improvements
in psychological and spiritual well-being, meaning and post-traumatic growth in the IG compared to CG 6 months
after baseline.
Discussion: Our study will contribute important statistical evidence on whether CALM can reduce depression and
existential distress in a German sample of advanced and highly distressed cancer patients.
Trial registration: ClinicalTrials.gov NCT02051660
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Background
Worldwide, eight million people died from cancer in
2010 - an increase of 38 % over the last two decades [1].
Numerous studies have shown high levels of symptom
burden and psychosocial distress associated with ad-
vanced cancer [2–6]. Psychological distress can range
from normal adaptive emotions through to higher levels
of severe and clinically significant symptoms that fulfill
the standardized diagnostic criteria for adjustment disorder,
anxiety disorders, or depression [7]. Studies demonstrate
a total prevalence for any mental disorder of 32 %
across all tumor settings and stages [8] and prevalence
rates of 30–50 % for all mood disturbances including
adjustment disorders and depression in palliative care
settings [9, 10].
Many patients with advanced disease experience
demoralization, existential and spiritual distress, or loss
of dignity [6, 11, 12], reflecting a loss of hope and a di-
minished sense of meaning [13–16]. In addition, patients
and caregivers are confronted with difficult treatment
decisions in palliative care planning.
Various types of psycho-oncological interventions are
associated with significant, small-to-medium effects on
emotional distress and quality of life [17]. However, the
majority of randomized controlled psycho-oncological
intervention trials for cancer patients were tested in
curative settings and predominantly included women
[17]. Manualized meaning-based interventions to treat the
psychosocial and existential distress in cancer patients
have been developed and empirically tested [18–21].
Nevertheless, the number of evaluated and effective
meaning-based psychotherapeutic interventions for ad-
vanced cancer patients is still small.
Psychotherapeutic interventions for individuals with
advanced disease must be short-term and flexible
enough to adjust to rapidly changing needs and clinical
circumstances. Only two of eight interventions described
in a review of meaning-based interventions for physically
ill patients by Lemay and Wilson [18] are short-term
[22, 23]. Although patients with advanced disease often
find it difficult to attend sessions at a fixed time in a
group setting, many existing psychotherapies for cancer
patients are conceptualized as group therapies [24].
Group settings in palliative care can cause additional
distress if patients are faced with the death of another
group member. Moreover, very few interventions focus
on addressing medical treatment situations in collabor-
ation with the medical care team [25].
Although psycho-oncological interventions have been
shown to significantly reduce symptoms of anxiety and
depression and enhance quality of life [17], the majority
of patients with advanced cancer do not receive psycho-
therapeutic interventions tailored to their individual
situation. To address this deficit in palliative care, Rodin
and colleagues developed a brief, manualized individual
psychotherapy for patients with advanced cancer:
Managing Cancer and Living Meaningfully (CALM)
[20, 26]. CALM aims to reduce depression and death
anxiety, to strengthen communication with health care
providers, and to enhance hope and meaning in life.
Given the lack of reliable data on the efficacy of
psycho-oncological interventions in palliative care set-
tings, we aim to examine the efficacy of CALM adapted
for German cancer care settings compared to a non-
manualized supportive psycho-oncological intervention
(SPI) using a randomized control trial design (RCT).
Methods
Study design
In this bicenter German CALM study we use a single-
blinded randomized-controlled trial design with two
treatment conditions: intervention group (IG) and con-
trol group (CG). Patients are assessed during screening,
at baseline (t0), after three (t1) and after 6 months (t2).
Participants are randomized between the intervention
and the control arm. Patients in the intervention group re-
ceive CALM, whereas patients in the control group receive
a usual non-manualized supportive psycho-oncological
intervention (SPI) to the same extent (frequency and dur-
ation) as CALM (Fig. 1).
Our CALM RCT is conducted in two University
Medical Centers: (a) the Outpatient Clinic for Psycho-
oncology at the Department of Medical Psychology,
University Medical Center Hamburg-Eppendorf and (b)
the Outpatient Cancer Counseling Center at the Section
of Psychosocial Oncology, Department of Medical
Fig. 1 Study (RCT) design (German CALM RTC)
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Psychology and Medical Sociology, University Medical
Center Leipzig. Our CALM RCT received ethics com-
mittee approval at both participating centers (Hamburg
reference number: PV4435; Leipzig reference number:
143–14–14042014).
Pilot phase
We conducted a pilot study prior to initiating the CALM
RCT at the Outpatient Clinic for Psycho-oncology,
Department of Medical Psychology, University Medical
Center Hamburg-Eppendorf. We implemented this initial
study phase over a 6-month period in order to test the
standard operating procedures and to evaluate the feasibil-
ity of CALM in our setting. Patient recruitment followed
the procedure outlined for the CALM RCT, except (a) pa-
tients were not screened for distress (DT/PHQ-9) to be
considered eligible for the study and (b) there was no
randomization: all participants were assigned to the inter-
vention condition. Our pilot phase included an evaluation
of each CALM therapy session and a semi-structured
interview after completing at least three therapy sessions.
The semi-structured interview focused on how partici-
pants experienced or evaluated (a) the overall CALM ther-
apy; (b) each of the four CALM dimensions; (c) the
therapeutic alliance, and (d) the structure and timeframe
of CALM.
Description of the experimental (CALM) and control (SPI)
interventions
Managing Cancer and Living Meaningfully (CALM)
Patients in the IG receive the brief, individual, manua-
lized CALM intervention [20, 26]. This semi-structured
psychotherapeutic intervention was designed for pa-
tients with advanced cancer and is based on empirical
research results, clinical observations and theoretical
concepts of supportive-expressive, existential, and psy-
chodynamic therapy as well as stress- and problem-
solving trainings. CALM covers the following four
domains:
(1)Symptom management and communication with
health care providers: Within this domain,
cooperation and improvement of communication
with health care providers, and help regarding
medical decision-making to ensure best care and
control of symptoms are addressed;
(2)Changes in self and relations with close others:
Within this domain, supporting the adjustment of
self-esteem and identity to cancer-related changes,
also in regard to relationships with close others, and
sustaining and providing required care and support
are addressed;
(3)Spirituality, sense of meaning and purpose: Within this
domain, understanding the individual meaning of
suffering and dying, and evaluation of priorities and
goals facing an advanced disease are addressed;
(4)Preparing for the future, sustaining hope and facing
mortality: Within this domain, acknowledgment of
anticipatory fears, balancing life and death, planning
advanced treatment, and preparing the process of
dying are addressed.
In each CALM session, the patient decides which
one of these domains and to what extent each domain
is covered depending on their current concerns and
supportive care needs. During a period of 6 months,
patients in the IG receive up to eight sessions of indi-
vidual therapy, each lasting 50 min.
Non-manualized supportive psycho-oncological intervention
(SPI)
Patients in the CG receive a non-manualized supportive
psycho-oncological intervention, which is regularly con-
ducted by psychotherapists at both study centers, the
Outpatient Cancer Counseling Center at the Section of
Psychosocial Oncology, Department of Medical Psych-
ology and Medical Sociology, University Medical Center
Leipzig, and the Outpatient Clinic for Psycho-oncology
at the Department of Medical Psychology, University
Medical Center Hamburg-Eppendorf. The therapeutic
approach is based on an integrative approach consisting
of psycho-oncological counseling, information, crisis
intervention as well as supportive individual therapy. As
IG patients, CG patients receive up to eight sessions of
individual therapy during a period of 6 months, each
session lasting 50 min.
Participants and procedure
We are recruiting patients at both study centers in
Hamburg and Leipzig as well as in local university
cancer care units and external cancer care facilities. Pa-
tients with advanced cancer are contacted by a study re-
search assistant and assessed for eligibility by using the
depression module of the Patient Health Questionnaire
(PHQ-9) [27–29] and the Distress Thermometer (DT) [30]
as screening tools. Patients fulfilling the inclusion criteria
are subsequently invited to a face-to-face interview with the
research assistant to receive comprehensive information
about our RCT. Further inclusion and exclusion criteria are
evaluated. The study research assistant conducts the Short
Orientation Memory Concentration test (SOMC) [31, 32]
and the depression section of the Structured Clinical Inter-
view for DSM-IV (SCID-I) [33] to evaluate whether pa-
tients meet the criteria for a major depressive disorder. If
patients meet all inclusion criteria and are willing to
participate, they are randomized (single-blinded) in ei-
ther the intervention or the control group. At the end
of the face-to-face interview patients receive the
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baseline questionnaire with a prepaid envelope and are
asked to return it within 2 weeks.
All patients provide written informed consent prior to
participation. Principles of good research practice are
strictly adhered to in this project including data and pa-
tients’ privacy protection. Patients can withdraw their in-
formed consent at all times without having to fear any
disadvantage in their medical or psychological treatment. In
case patients decide not to participate in the study or to
withdraw informed consent, reasons as well as basic demo-
graphic and medical characteristics (age, sex, diagnosis, date
of diagnosis, educational background) are documented on a
voluntary basis. These data will be used to conduct non-
responder analyses and identify a potential sample bias.
Eligibility for study participation
Study inclusion criteria
We include patients with (a) a malignant solid tumor who
have (b) tumor stages of III or IV in accordance to the
UICC classification, including advanced disease in case of
sarcoma, melanoma and endocrine tumors, which implies
average life expectancies between 12 and 18 months.
Patients who are included in the study (c) are at least
18 years old, (d) speak German fluently, (e) score greater
than or equal to nine on the PHQ-9 or/and greater than
or equal to five on the Distress Thermometer (DT). It is
further necessary that (f) there is no evidence of severe cog-
nitive impairments in the patient’s records or indicated by
his or her physician or oncologist, as this would interfere
with the practical performance of the psychotherapeutic in-
terventions (CALM and SPI).
Study exclusion criteria
During the face-to-face interview the study research
assistant evaluates the following exclusion criteria: (a)
deficits in communication, (b) lack of willingness or in-
ability to attend all of the necessary therapy sessions
and (c) acute suicidality (concrete suicidal thoughts
and/or plans, in which case psychiatric care is provided
immediately). Patients who (d) score less than 20 points
on the Short Orientation-Memory-Concentration test
(SOMC) or (e) show a level of less than 70 on the Kar-
nofsky index are excluded, because life expectancy in that
case is expected to be less than 6 months [34, 35]. Patients
will be further excluded from the study in case they re-
ceive parallel psychotherapy. Previous experiences with
psychotherapy as well as concurrent psychopharmaco-
logical treatment are documented but are no reasons
to be excluded from study participation.
Later study exclusion criteria
Patients will be excluded from the study, if exclusion
criteria occur during the intervention (e.g. cognitive im-
pairments) or if patients show signs of acute suicidality
(concrete thoughts and/or plans to commit suicide), in
which case psychiatric care will be provided immedi-
ately. At the point of exclusion, study results up to this
date and reasons for exclusion will be documented.
These data will be further analyzed in the drop-out
analysis.
Randomization procedure
Study participants are randomly assigned to receive
either CALM or SPI. The random allocation sequence
(randomization list) was generated by the Institute of
Medical Biometry and Epidemiology at the University
Medical Center Hamburg-Eppendorf. Randomization
is stratified according to sex. After a patient gives writ-
ten informed consent for study participation, a study
research assistant reports the patients’ initials, date of
birth and sex to a blinded research assistant at the Uni-
versity Medical Center in Leipzig. The research assistant
includes the patient in the randomization list and informs
the research assistant about treatment allocation (CALM or
SPI). No CALM study member and research assistant has
access to the randomization list. The patient is not in-
formed about their treatment condition.
Assessment
Baseline assessment
The baseline questionnaire (t0) is handed to the patient
by the research assistant at the end of the face-to-face
interview and includes all primary and secondary out-
come measures, except for the PHQ-9 depression inven-
tory and the Distress Thermometer, which have been
used as screening instruments to assess eligibility prior
to the interview, and the GAD-7 anxiety inventory
(Table 1).
Follow-up assessments
Two follow-up assessments are realized at three (t1) and
6 months (t2) following the baseline assessment. The
follow-up assessments ideally correspond with the com-
pletion of the third or fourth and the sixth to eighth
CALM therapy session. Participants receive the study
questionnaires with a prepaid envelope and are asked to
return them within 2 weeks. Those have not returned
the study questionnaires within 2 weeks receive a re-
minder. If patients do not reply within one week after
the reminder, the study research assistant will contact
them by phone. The follow-up measures include the as-
sessment of changes in demographics as well as medical
and treatment-related events (e. g. new diagnoses or
complications, hospitalization in the past 3 months,
whether patient signed a living-will in the past 3 months)
and other significant life events.
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Evaluation of individual therapy sessions
Following each CALM or SPI therapy session, patients and
therapists complete the Clinical Evaluation Questionnaire
[36]. This questionnaire measures to what extent patients
perceived their therapy session as helpful, and to what ex-
tent therapists felt they were supportive to the relevant
aspects.
Both treatment conditions (IG and CG) end after
6 months and a maximum of eight sessions. Therefore,
the last outcome assessment of the study takes place
after 6 months and a maximum of eight sessions. If
there is a further need for psychosocial support we offer
participants the possibility to receive further treatment
after study completion – either by their study therapist
or a newly assigned one, according to capacity.
Quality standards and therapists training
The CALM treatment manual
We translated and adapted the CALM treatment manual
[37] into the German language.
Therapist qualifications
Our study therapists are certified psychologists with
additional psycho-oncological and/or psychotherapeutic
training. All study therapists are pair-randomized to the
treatment conditions (IG and CG) to minimize a pos-
sible bias.
CALM training
CALM therapists receive a comprehensive CALM training
at each study center in Hamburg or Leipzig. Therapists
randomized to the control condition do not receive any
additional training.
Supervision
To ensure the quality of the therapy under both treat-
ment conditions, both CALM and SPI therapists receive
regular supervision by experienced supervisors in separ-
ate groups. The supervisor of the IG has received the
same comprehensive CALM training.
Tape recording
Every therapy session in both treatment conditions is
audio taped. Our research team will analyze audio re-
cordings of randomly selected therapy sessions to evalu-
ate treatments regarding process quality.
Main study hypotheses
We hypothesize that patients in the CALM intervention
will show a significantly lower level of depression 6 months









Medical and treatment-related characteristics X X X
Short Orientation-Memory-Concentration test (SOMC) X
Structured Clinical Interview for DSM Disorders:
Major Depressive Disorder Module
(SCID–I) X
Distress Thermometer (DT) X X X
Depression module of the Patient Health Questionnaire (PHQ–9) X X X
Beck Depression-Inventory II (BDI–II) X X
Generalized Anxiety Disorder Questionnaire (GAD–7) X X X
Demoralization Scale (DS) X X X
Brief Fatigue Inventory (BFI) X X X
Memorial Symptom Assessment Scale Short Form (MSAS–SF) X X X
Functional Assessment of Chronic Illness Therapy-Spiritual
Well-Being Scale
(FACIT–SP) X X X
Death and Dying Distress Scale (DADDS) X X X
Posttraumatic Growth Inventory (PTGI) X X X
The Experience in Close Relationships Inventory
Modified Short Term Version
(ECR–M16) X X X
Quality of Life at the End of Life Cancer (QUAL–EC) X X X
Couple Communication Scale (CCS) X X X
Clinical Evaluation Questionnaire after every therapy session
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after baseline compared to patients in the control group
(SPI). We further hypothesize a significant reduction in
anxiety and fatigue as well as significant improvements in
psychological and spiritual well-being, meaning and post-
traumatic growth in the CALM intervention compared to
SPI 6 months after baseline.
Measures
Table 1 shows all study measures included in our CALM
RCT. We are collecting demographic information (e. g. age,
sex, marital status, education, occupational situation)
through a standardized questionnaire as well as medical
and treatment-related variables (e. g. cancer diagnosis, date
of diagnosis, past and current medical treatments) through
medical charts.
The Short Orientation-Memory-Concentration test
(SOMC) [31, 32] is a validated culture-fair instrument
for assessing orientation, memory and concentration.
The SOMC scores range from 0 to 28. Scores less than
20 indicate cognitive impairments.
The Structured Clinical Interview for DSM-IV (SCID-I)
[33] is a valid structured interview and the gold standard
for assessing DSM-IV Axis I disorders. We use the 15
items representing the DSM criteria for a major depressive
disorder in the face-to-face interview to screen whether
patients meet the criteria for a major depressive disorder.
The interviewer evaluates to what extent a patient’s answers
meet the depression criteria from one (criterion not met) to
three (criterion is fully met). To diagnose a major depres-
sive episode at least five out of nine symptoms need to be
scored with 3, one being item 1 or 2.
The German version of the Distress Thermometer (DT)
[30] is a valid and reliable self-report instrument for
screening psychological distress in cancer patients. The
single-item visual analogue scale ranges from 0 (no dis-
tress) to 10 (extreme distress) to quantify the global level
of distress and is accompanied by a standardized symp-
tom checklist. In our RCT, only the single-item visual
analogue scale is used. Scores equal to or higher than
five indicate significant psychological distress.
The Depression module of the Patient Health Question-
naire (PHQ-9) [27–29] is a valid self-report screening in-
strument for depression. It includes nine items, which
reflect the DSM-IV criteria for major depression. Items are
scored on a four-point Likert scale from 0 (not at all) to 3
(nearly every day) with a total score ranging from 0 to 27.
Scores up to four indicate absence of depression, scores
from five to nine indicate mild depression, scores from 10
to 15 indicate moderate depression, and scores higher than
15 indicate severe levels of depression [38]. The German
adaptation of the instrument shows high internal
consistency with Cronbach’s α = .89 [39].
The Beck Depression-Inventory II (BDI-II) [40] is a
valid self-report questionnaire evaluating the severity of
depression. The measure consists of 21 items, which re-
flect the DSM-IV symptom criteria for a major depres-
sive disorder. Items are scored on a four-point Likert-scale
rated from 0 (I don’t feel particularly guilty) to 3 (I feel
guilty all of the time) with a total score ranging from 0 to
63. Scores up to 13 indicate none or minimal depression,
scores from 14 to 19 indicate mild depression, scores from
20 to 28 indicate moderate depression and scores higher
than 29 indicate severe depression. The German BDI-II
version [40] shows high internal consistency with
Cronbach’s α ≥.84 for various samples [41].
The Generalized Anxiety Disorder Questionnaire
(GAD-7) [42, 43] is a brief self-report questionnaire
assessing generalized anxiety disorder. It includes seven
items, which reflect the DSM-IV symptom criteria for
generalized anxiety disorder. Items are scored on a four-
point Likert scale ranging from 0 (not at all) to 3 (nearly
every day) with a total score ranging from 0 to 21. Scores
up to 4 indicate absence of anxiety, scores from 5 to 9 indi-
cate mild anxiety, scores from 10 to 15 indicate moderate
anxiety, and scores higher than15 indicate severe levels of
anxiety. The German adaptation of the instrument shows
high internal consistency with Cronbach’s α = .89.
The German version of the Demoralization Scale (DS)
[44, 45] is a validated self-report instrument measuring
demoralization [46]. The scale includes 24 items repre-
senting four subscales: loss of meaning and purpose,
dysphoria, disheartenment and sense of failure. Items
are scored on a five-point Likert scale ranging from 0
(never) to 4 (all the time) with a total score ranging from
0 to 96. Scores less than or equal to 30 indicate low
demoralization whereas a score greater than 30 indicate
high demoralization. The German version shows high
internal consistency with Cronbach’s α = 0.84 [45].
The Brief Fatigue Inventory (BFI) [47, 48] is a short,
validated instrument for assessing the severity of fatigue
in cancer patients. After patients stated whether they felt
unusually tired or fatigued during the past week, nine
items measure experienced fatigue as well as its interfer-
ence with certain aspects of patients’ lives within the last
24 h. Fatigue is rated on an eleven-point Likert-scale
from 0 (no fatigue/does not interfere) to 10 (as bad as
you can imagine/completely interferes). The mean BFI
score is calculated from the nine items, with 1–4 indicat-
ing mild, 5–6 moderate and 7–10 severe fatigue. The
German version shows high internal consistency with
Cronbach’s α = 0.92 [48].
The Memorial Symptom Assessment Scale (MSAS)
[49, 50] is a validated self-report instrument assessing
the number of physical problems that may occur as a
result of cancer or its treatment. For our study we use
the list of symptoms suggested by Chang et al. [50] in
their adapted version (MSAS-Short Form). The MSAS-
SF assesses symptom frequency and resulting distress
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only. Items are scored on a five-point Likert-scale ran-
ging from 0 (not at all) to 4 (very much). The average
symptom score is calculated. The scale shows high in-
ternal consistency with Cronbach’s α = 0.87. We did
not include the four psychological items of the MSAS-
SF in our study because we assess psychological symp-
toms using other validated instruments.
The German version of the Functional Assessment of
Chronic Illness Therapy-Spiritual Well-Being Scale
(FACIT-SP) [51] is part of the FACIT measurement sys-
tem. The self-report instrument measures in what way
spirituality and religion contribute to the quality of life
of cancer patients on the two subscales meaning/peace
and faith. Items are scored on a five-point Likert-scale
from 0 (not at all) to 4 (very much) with a total score
ranging from 0 to 48, high scores indicating higher spir-
itual well-being. Subscales and the sum score show high
internal consistency with Cronbach’s α = .80.
The Death and Dying Distress Scale (DADDS) [52, 53]
is a self-report instrument assessing specific concerns of
advanced cancer patients concerning insecurity about
ones end of life, being a burden to others, as well as lost
time and opportunities. The German adaptation includes
nine instead of 15 items. Additionally, the Likert-scale
was changed from a six-point to a five-point Likert-scale
with mild and moderate distress put together to one
label. Items can be scored from 0 (no distress) to 4 (very
much distress), resulting in a sum score from 0 to 36, a
higher score indicating higher distress.
The German version of the Posttraumatic Growth In-
ventory (PTGI) [54, 55] is a self-report instrument asses-
sing personal posttraumatic growth after a traumatic
event. It consists of 21 items representing four subscales:
new possibilities, relating to others, appreciation of life
and spiritual change. Patients are asked if their life chan-
ged because of their cancer diagnosis. Items are scored
on a three-point Likert-scale ranging from 0 (not at all)
to 2 (very much) with a total score ranging from 0 to 42,
a high score indicating high posttraumatic growth. The
German version shows high internal consistency with
Cronbach’s α = 0.92 [55].
The Experiences in Close Relationships Scale (ECR-
M16) [56, 57] is a self-report instrument assessing pa-
tients’ experiences in close romantic as well as non-
romantic relationships on two subscales anxiety and
avoidance. It is a shorter version of the ECR-36 [56] in-
cluding 16 items due to usage in groups of highly dis-
tressed patients. Items are scored on a seven-point
Likert-scale ranging from 1 (disagree) to 7 (agree) with
a total score ranging from 16 to 56 on each subscale.
Higher scores on one or both subscales indicate high
attachment insecurity. Both subscales show high in-
ternal consistency with Cronbach’s α = 0.91 (anxiety)
and α = 0.88 (avoidance) [57].
The Quality of Life at the End of Life Cancer (QUAL-EC)
[58] is a self-report instrument assessing quality of life in
patients at the end of their lives regarding their perception
of a good death. The instrument includes five subscales:
symptom control, relationship with health care provider,
preparation for end of life and life completion. It includes
17 items, the first three items measuring symptom control
and referring to three physical or emotional symptoms the
patient has to name at the beginning. We used items 4–17
measuring the remaining three subscales. Items are scored
on a five-point Likert-scale ranging from 1 (not at all) to 5
(completely) with a total score ranging from 14 to 70, high
scores indicating high quality of life. The instrument shows
high internal consistency with Cronbach’s α = 0.83.
The Couple Communication Scale (CCS) [59] is an
online-measure for assessing communication, conflict
solution and relationship satisfaction in romantic rela-
tionships and was developed as a part of the ENRICH/
PREPARE program [60]. The scale is part of the Couple
Checkup Scale which includes 32 items covering – de-
pending on relationship status (dating, engaged, mar-
ried) – different aspects of romantic relationships that
were found to be important for a happy marriage. In ac-
cordance with G. Rodin and colleagues we only used the
ten items depicting communication in romantic relation-
ships in our study. Items can be scored from 1 (strongly
disagree) to 5 (strongly agree).
The Clinical Evaluation Questionnaire [36] is a self-
report seven-item questionnaire assessing the extent to
which a therapeutic session was perceived as helpful for
patients on such dimensions as being able to discuss
their concerns about cancer and their treatment options
and to clarify their values. The questionnaire is answered
on a five-point Likert scale, ranging from 0 (not at all) to
4 (very much). Higher values indicate a higher degree of
perceived benefit. If a certain aspect is not relevant,
items can be rated as not applicable.
In case there was no German adaptation of the instru-
ment available, we used state-of-the-art forward- back-
translation by two independent research assistants.
Statistical methods
Power calculation
To determine the sample size in a design in which two
groups are compared at follow-up, controlling for baseline
scores, we used the formula n = [2(ZA + ZB)
2 (1 − r2)/d2] + 1
suggested by Borm [61]. In a longitudinal study by Rodin et
al. [25], a correlation of. 72 (based on n=137)between de-
pression scores (BDI-II) at baseline and 6 months, as well
as a SD of 7.4 at baseline were observed. Therefore, we
used r = .70 and SD = 7.4 as our estimates. The goal of this
RCT is to detect an effect size of Cohen’s d = .405 (d = (X1
−X2)/SD) [62] in depression scores between both groups
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(i.e. (X1 −X2) = d*SD = .405*7.4 = 3). Considering these fac-
tors, a minimum of 50 participants is required at t2.
The number of participants that need to be recruited
per group at baseline is calculated by taking into account
the effects of loss to follow-up and non-compliance
using the formula n-b = ne (1/p) (1/c
2 [63, 64]. Based on
trial completion rates and compliance rates at 6 months
observed in similar trials, we estimate a completion rate
of 60 % (i.e. loss to follow-up rate of 40 %) and an 80 %
compliance rate [65, 66]. Therefore, we need to recruit
131 participants per group, or 262 total participants at
baseline. Recruitment is equally divided between Hamburg
and Leipzig, resulting in a number of 66 IG patients and 66
CG patients for Hamburg and 65 patients in each group for
Leipzig. The adjustment for non-compliance is conservative
as it assumes that non-compliant experimental participants
will respond as though they were control participants.
Statistical analysis
For the final analyses we will use an intention-to-treat
approach (ITT) and compare patients in the assigned
treatment groups. Main analyses to evaluate efficacy
based on primary (depression) and secondary outcomes
at 6 months follow-up (primary endpoint) will be per-
formed using analysis of covariance (ANCOVA). In case
of missing outcome data at the primary endpoint, we
use the last observation carried forward (LOCF) method.
Controlling for baseline test scores as well as demographic
and disease-related characteristics, we hypothesize that the
mean depression score in the IG will be lower than the one
in the CG. Other analyses will include a mixed model ap-
proaches (to examine changes over time), regression ana-
lyses (controlling for additional factors), and exploratory
analyses (of treatment effect modifiers).
Discussion
In the last decades, existential and psychosocial needs of
patients in palliative care became increasingly the focus
of attention in clinical practice and research. The new
World Health Organization (WHO) palliative care reso-
lution ‘Strengthening of palliative care as a component
of integrated treatment within the continuum of care’
just recently made clear that palliative care is aimed to
be integrated as an essential component of health care
systems worldwide [67]. In this resolution the WHO
Executive Board explicitly refers to psychosocial and
spiritual problems and their treatment. Despite the
pronounced necessity for better psychosocial care in
palliative treatment, recent studies investigating the ef-
fectiveness of psycho-oncological interventions are
mostly including patients in earlier stages of the cancer
disease. Most RCTs have small sample sizes and com-
pare one active intervention against an inactive control
group, no treatment, or care as usual [17].
Our CALM RCT adapted to German cancer care set-
tings addresses the urgent need for developing, optimiz-
ing and evaluating manualized psycho-oncologic
interventions for advanced cancer patients. To ensure
optimal treatment for advanced patients’ specific existen-
tial and psychosocial strains it aims to close the gap of
treatment options by implementing a short-term, indi-
vidual and meaning-based intervention.
CALM is already under examination in a RCT in
Toronto, Canada, by the research group of Prof. G.
Rodin who developed CALM. Our RCT is conducted in
close cooperation with the Canadian research group,
which ensures research quality and helps us to be pre-
pared for possible risks and obstacles during the trial.
Currently, studies examining CALM are also conducted
in Italy and the United Kingdom, which will lead to a
growing international application of the intervention as
a psychological dimension of early palliative care. As one
of the few psycho-oncological interventions dealing with
these issues, our study will contribute important statis-
tical evidence on whether CALM can reduce depression
and existential distress in a German sample of advanced
and highly distressed cancer patients.
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